177 related articles for article (PubMed ID: 21044186)
1. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
Nonaka D; Henley JD; Chiriboga L; Yee H
Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
[TBL] [Abstract][Full Text] [Related]
7. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
9. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms.
Datta MW; Shahsafaei A; Nadler LM; Freeman GJ; Dorfman DM
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):210-5. PubMed ID: 10981873
[TBL] [Abstract][Full Text] [Related]
10. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China.
Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN
Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452
[TBL] [Abstract][Full Text] [Related]
12. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
[TBL] [Abstract][Full Text] [Related]
13. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.
Kaira K; Murakami H; Serizawa M; Koh Y; Abe M; Ohde Y; Takahashi T; Kondo H; Nakajima T; Yamamoto N
Virchows Arch; 2011 May; 458(5):615-20. PubMed ID: 21253760
[TBL] [Abstract][Full Text] [Related]
14. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
Pomplun S; Wotherspoon AC; Shah G; Goldstraw P; Ladas G; Nicholson AG
Histopathology; 2002 Feb; 40(2):152-8. PubMed ID: 11952859
[TBL] [Abstract][Full Text] [Related]
17. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.
Fukumoto K; Taniguchi T; Ishikawa Y; Kawaguchi K; Fukui T; Kato K; Matsuo K; Yokoi K
Eur J Cardiothorac Surg; 2012 Dec; 42(6):e152-6. PubMed ID: 23024234
[TBL] [Abstract][Full Text] [Related]
18. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
[TBL] [Abstract][Full Text] [Related]
19. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
20. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies.
Benveniste MF; Moran CA; Mawlawi O; Fox PS; Swisher SG; Munden RF; Marom EM
J Thorac Oncol; 2013 Apr; 8(4):502-10. PubMed ID: 23446204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
